Stone David H, Brewster David C, Kwolek Christopher J, Lamuraglia Glenn M, Conrad Mark F, Chung Thomas K, Cambria Richard P
Division of Vascular and Endovascular Surgery and the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
J Vasc Surg. 2006 Dec;44(6):1188-97. doi: 10.1016/j.jvs.2006.08.005.
Pivotal and comparative trial data are emerging for stent graft (SG) vs open repair of the thoracic aorta. We reviewed procedure-related perioperative morbidity, mortality, and mid-term outcomes in a contemporary series of patients treated with SG of the thoracic aorta. The data were compared with those of a patient cohort concurrently treated with open surgical repair confined to the descending aorta.
A review of patients undergoing SG procedures and open surgery of the thoracic aorta from January 1, 1996, to November 30, 2005, was performed from a prospectively compiled database. Study end points included perioperative complications, late survival, freedom from reinterventions, and graft-related complications. Multivariate methods were used to assess variables potentially associated with study end points; late outcomes were compared with actuarial methods.
In 105 patients (mean age, 70 years; 66 male [62.9%]) SG repairs were done for 68 degenerative aneurysms (64.7%), 12 penetrating ulcers (11.4%), 15 pseudoaneurysms (14.3%), 9 traumatic tears (8.6%), and 1 acute dissection (0.9%). Mean follow-up was 22 months (range, 0 to 101 months). Eighty-nine (84.8%) SG patients were asymptomatic at presentation and underwent elective repair, whereas 16 (15.2%) presented with acute conditions and underwent urgent repair. Perioperative mortality was 7.6% (8/105), and actuarial survival at 48 months was 54% +/- 7%. The perioperative mortality rate among SG patients treated for degenerative pathology was 10.4% (8/77). Seven (6.7%) of 105 patients experienced spinal cord ischemic complications, including 2 patients with transient paraparesis that resolved by the time of discharge. Reinterventions were performed in 10.5% of patients (11/105), with freedom from reintervention approaching 81% by 48 months. Over the same interval, 93 patients were treated with open-surgical repair for descending thoracic aneurysm (anastomosis cephalad to the celiac axis). Perioperative mortality in the open cohort was 15.1% (14/93; P = .09 vs SG repair), and the 48-month actuarial survival was 64% +/- 6%. The incidence of spinal cord ischemic complications was 8.6% (8/93), including 4 patients with transient paraparesis (P = .44 vs SG repair). Nine patients (9.7%) required surgical reintervention during the follow-up period, with 48-month freedom from reintervention approaching 79% (P = .73 vs SG repair).
Operative mortality was halved with SG, with similar late survival for both cohorts. Reinterventions were required at a nearly identical rate for open repair and SG, and both groups experienced similar rates of spinal cord ischemic complications.
关于支架型人工血管(SG)与胸主动脉开放修复术的关键及对比试验数据不断涌现。我们回顾了当代一系列接受胸主动脉SG治疗患者的手术相关围手术期发病率、死亡率及中期结果。将这些数据与同期接受降主动脉开放手术修复患者队列的数据进行比较。
从一个前瞻性编制的数据库中,回顾了1996年1月1日至2005年11月30日期间接受胸主动脉SG手术和开放手术的患者。研究终点包括围手术期并发症、远期生存率、无需再次干预及人工血管相关并发症。采用多变量方法评估可能与研究终点相关的变量;采用精算方法比较远期结果。
105例患者(平均年龄70岁;66例男性[62.9%])接受SG修复,其中68例为退行性动脉瘤(64.7%),12例为穿透性溃疡(11.4%),15例为假性动脉瘤(14.3%),9例为创伤性撕裂(8.6%),1例为急性夹层(0.9%)。平均随访22个月(范围0至101个月)。89例(84.8%)SG患者就诊时无症状,接受择期修复,而16例(15.2%)表现为急性病症,接受急诊修复。围手术期死亡率为7.6%(8/105),48个月时的精算生存率为54%±7%。因退行性病变接受治疗的SG患者围手术期死亡率为10.4%(8/77)。105例患者中有7例(6.7%)发生脊髓缺血并发症,包括2例出院时短暂性截瘫已缓解的患者。10.5%的患者(11/105)接受了再次干预,到48个月时无需再次干预的比例接近81%。在同一时期,93例患者接受降胸段动脉瘤开放手术修复(吻合口位于腹腔干上方)。开放手术组的围手术期死亡率为15.1%(14/93;与SG修复相比,P = 0.09),48个月时的精算生存率为64%±6%。脊髓缺血并发症的发生率为8.6%(8/93),包括4例短暂性截瘫患者(与SG修复相比,P = 0.44)。9例患者(9.7%)在随访期间需要手术再次干预,48个月时无需再次干预的比例接近79%(与SG修复相比,P = 0.73)。
SG使手术死亡率减半,两组远期生存率相似。开放修复和SG的再次干预率几乎相同,两组脊髓缺血并发症发生率相似。